Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.

Therapeutic Drug Monitoring
Sally V J BowskillMaxine X Patel

Abstract

Information on the plasma risperidone and total 9-hydroxyrisperidone concentrations ('total risperidone') attained in clinical practice is scant. The aim of this work was to gather such information to better inform the interpretation of results. This involved the audit of plasma total risperidone data from a risperidone therapeutic drug monitoring service 2002-2010. There were 586 samples from 411 patients [289 (70%) males aged at the time of the first sample (median, range) 37 (7-83) years and 121 females aged 42 (10-91) years]. In patients aged 18 years and over, the mode of risperidone administration was oral: 242 samples (163 patients), risperidone long-acting injection (RLAI): 42 samples (39 patients), both oral and RLAI: 18 samples (12 patients), no information: 266 samples (211 patients). No risperidone/9-hydroxyrisperidone was detected in 10% of the samples, including 5 samples from patients prescribed RLAI. In the remainder, the mean (SD) total plasma total risperidone was all samples 35 (36), oral only 33 (29), RLAI only 23 (16), oral and RLAI 50 (21) μg/L. Overall, only 45% of the samples had plasma total risperidone within the range 20-59 mcg/L. Multiple linear regression analysis (95 samples) revealed that sex, smo...Continue Reading

References

Aug 26, 1998·Therapeutic Drug Monitoring·O V OlesenK Linnet
Mar 14, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·M C MauriP Papa
Aug 23, 2001·Forensic Science International : Synergy·R J FlanaganE P Spencer
Jul 2, 2004·Therapeutic Drug Monitoring·Christoph HiemkeMatthias J Müller
Jul 13, 2004·Schizophrenia Research·Mariëlle EerdekensErik Mannaert
Nov 12, 2005·Journal of Clinical Psychopharmacology·Manabu SaitoSunao Kaneko
Mar 4, 2006·The American Journal of Psychiatry·Gary RemingtonShitij Kapur
Jun 24, 2008·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Marc De MeulderPhilip M M B L Timmerman
Jun 10, 2011·Clinical Pharmacokinetics·Erin SchwengerMary H H Ensom
Jun 23, 2011·Journal of Clinical Psychopharmacology·Maxine X PatelRobert James Flanagan

❮ Previous
Next ❯

Citations

Dec 11, 2013·Journal of Analytical Toxicology·Kristian Linnet, Sys Stybe Johansen
Jul 23, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·D M TaylorO Dzahini
May 5, 2016·Basic & Clinical Pharmacology & Toxicology·Espen MoldenTore Haslemo
Oct 17, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David M TaylorOlubanke Dzahini
Jun 5, 2015·Journal of Psychopharmacology·Suzanne LawMaxine X Patel
Jul 13, 2017·Expert Review of Clinical Pharmacology·Georgios SchoretsanitisJose de Leon
Aug 25, 2015·Therapeutic Advances in Psychopharmacology·Suzanne LawMaxine X Patel
Jan 7, 2020·Mass Spectrometry Reviews·Jia-Jia CuiJi-Ye Yin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.